Cargando…
Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study
Statins constitute the mainstay treatment for atherosclerotic cardiovascular disease, which is associated with the risk of new-onset diabetes mellitus (NODM). However, the effects of individual statins on the risk of NODM remain unclear. We recruited 48,941 patients taking one of the three intereste...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696728/ https://www.ncbi.nlm.nih.gov/pubmed/33202854 http://dx.doi.org/10.3390/biomedicines8110499 |
_version_ | 1783615470417477632 |
---|---|
author | Liu, Wei-Ting Lin, Chin Tsai, Min-Chien Cheng, Cheng-Chung Chen, Sy-Jou Liou, Jun-Ting Lin, Wei-Shiang Cheng, Shu-Meng Lin, Chin-Sheng Tsao, Tien-Ping |
author_facet | Liu, Wei-Ting Lin, Chin Tsai, Min-Chien Cheng, Cheng-Chung Chen, Sy-Jou Liou, Jun-Ting Lin, Wei-Shiang Cheng, Shu-Meng Lin, Chin-Sheng Tsao, Tien-Ping |
author_sort | Liu, Wei-Ting |
collection | PubMed |
description | Statins constitute the mainstay treatment for atherosclerotic cardiovascular disease, which is associated with the risk of new-onset diabetes mellitus (NODM). However, the effects of individual statins on the risk of NODM remain unclear. We recruited 48,941 patients taking one of the three interested statins in a tertiary hospital between 2006 and 2018. Among them, 8337 non-diabetic patients taking moderate-intensity statins (2 mg/day pitavastatin, 10 mg/day atorvastatin, and 10 mg/day rosuvastatin) were included. The pitavastatin group had a higher probability of being NODM-free than the atorvastatin and rosuvastatin groups during the 4-year follow-up (log-rank test: p = 0.038). A subgroup analysis revealed that rosuvastatin had a significantly higher risk of NODM than pitavastatin among patients with coronary artery disease (CAD) (adjusted HR [aHR], 1.47, 95% confidence interval [CI], 1.05–2.05, p = 0.025), hypertension (aHR, 1.26, 95% CI, 1.00–1.59, p = 0.047), or chronic obstructive pulmonary disease (COPD) (aHR, 1.74, 95% CI, 1.02–2.94, p = 0.04). We concluded that compared with rosuvastatin, reduced diabetogenic effects of pitavastatin were observed among patients treated with moderate-intensity statin who had hypertension, COPD, or CAD. Additional studies are required to prove the effects of different statins on the risk of NODM. |
format | Online Article Text |
id | pubmed-7696728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76967282020-11-29 Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study Liu, Wei-Ting Lin, Chin Tsai, Min-Chien Cheng, Cheng-Chung Chen, Sy-Jou Liou, Jun-Ting Lin, Wei-Shiang Cheng, Shu-Meng Lin, Chin-Sheng Tsao, Tien-Ping Biomedicines Article Statins constitute the mainstay treatment for atherosclerotic cardiovascular disease, which is associated with the risk of new-onset diabetes mellitus (NODM). However, the effects of individual statins on the risk of NODM remain unclear. We recruited 48,941 patients taking one of the three interested statins in a tertiary hospital between 2006 and 2018. Among them, 8337 non-diabetic patients taking moderate-intensity statins (2 mg/day pitavastatin, 10 mg/day atorvastatin, and 10 mg/day rosuvastatin) were included. The pitavastatin group had a higher probability of being NODM-free than the atorvastatin and rosuvastatin groups during the 4-year follow-up (log-rank test: p = 0.038). A subgroup analysis revealed that rosuvastatin had a significantly higher risk of NODM than pitavastatin among patients with coronary artery disease (CAD) (adjusted HR [aHR], 1.47, 95% confidence interval [CI], 1.05–2.05, p = 0.025), hypertension (aHR, 1.26, 95% CI, 1.00–1.59, p = 0.047), or chronic obstructive pulmonary disease (COPD) (aHR, 1.74, 95% CI, 1.02–2.94, p = 0.04). We concluded that compared with rosuvastatin, reduced diabetogenic effects of pitavastatin were observed among patients treated with moderate-intensity statin who had hypertension, COPD, or CAD. Additional studies are required to prove the effects of different statins on the risk of NODM. MDPI 2020-11-13 /pmc/articles/PMC7696728/ /pubmed/33202854 http://dx.doi.org/10.3390/biomedicines8110499 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Liu, Wei-Ting Lin, Chin Tsai, Min-Chien Cheng, Cheng-Chung Chen, Sy-Jou Liou, Jun-Ting Lin, Wei-Shiang Cheng, Shu-Meng Lin, Chin-Sheng Tsao, Tien-Ping Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study |
title | Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study |
title_full | Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study |
title_fullStr | Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study |
title_full_unstemmed | Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study |
title_short | Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study |
title_sort | effects of pitavastatin, atorvastatin, and rosuvastatin on the risk of new-onset diabetes mellitus: a single-center cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696728/ https://www.ncbi.nlm.nih.gov/pubmed/33202854 http://dx.doi.org/10.3390/biomedicines8110499 |
work_keys_str_mv | AT liuweiting effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy AT linchin effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy AT tsaiminchien effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy AT chengchengchung effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy AT chensyjou effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy AT lioujunting effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy AT linweishiang effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy AT chengshumeng effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy AT linchinsheng effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy AT tsaotienping effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy |